Overview

Combined Anabolic Therapy

Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Phase:
PHASE4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Treatments:
romosozumab
Teriparatide